Skip to content
2000
Volume 26, Issue 15
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that helps to reduce cardiovascular events. This clinical result is attributable primarily to the crucial involvement of PCSK9 in regulating the low-density lipoprotein cholesterol level. Because oral anti-PCSK9 medications have yet to be available, the benefits of this unique treatment approach have been diminished. Identifying naturally occurring PCSK9 inhibitors may lead to considerable progress in this regard. These inhibitors serve as a starting point for producing oral and effective components that could be used with statins to boost the proportion of patients who achieve their LDL-cholesterol goals. In this review, we have briefly summarised the recent information regarding natural components or extracts that have been shown to inhibit PCSK9 activity.

Loading

Article metrics loading...

/content/journals/cchts/10.2174/1386207326666230627122630
2023-12-01
2025-09-10
Loading full text...

Full text loading...

/content/journals/cchts/10.2174/1386207326666230627122630
Loading

  • Article Type:
    Review Article
Keyword(s): cholesterol; ER; inhibitors; LDL; monoclonal antibodies; PCSK9
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test